Collateral for a security interest recorded Sep 11, 2026 (Truist Bank).
Term ends Jul 27, 2032 · High confidence
20-year base term ends Jul 27, 2032
Held by Commave Therapeutics S.A.
Filed May 15, 2014 as application 14/234,440 · Granted Jul 14, 2015
Base term, 20 years from filing
Today
2012
2032
Clock starts
Jul 27, 2012
Jul 27, 2012
Term ends
Jul 27, 2032
Jul 27, 2032
Granted
Jul 14, 2015
Jul 14, 2015
base term
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 27, 2012, when application PCT/US2012/048641, the earliest non-provisional in its chain, was filed (this one was filed May 15, 2014) | Jul 27, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 27, 2032 | High confidence |
This family
| US 9,079,928 | this patent Jul 2032 | Jul 2032 |
| US 9,453,037 | In force Jul 2032 | Jul 2032 |
| US 10,231,960 | In force Jul 2032 | Jul 2032 |
| Application 16/244,460 | Abandoned not computed | not computed |
4 of 5 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 25, 2014 Reel 32755, frame 674 | Guenther, Sven; Chi, Guochen; Bera, Bindu; Mickle, Travis; Bera, Sanjib | Kempharm, Inc. | Assignment of Assignor's Interest |
| Jun 3, 2014 Reel 33079, frame 927 | Kempharm, Inc. | Deerfield Private Design Fund III, L.P. | Security Interest |
| Aug 21, 2014 Reel 33580, frame 775 | Guenther, Sven; Chi, Guochen; Bera, Bindu; Mickle, Travis; Bera, Sanjib | Kempharm, Inc. | Assignment of Assignor's Interest |
| Aug 28, 2014 Reel 33648, frame 173 | Guenther, Sven; Chi, Guochen; Bera, Bindu; Mickle, Travis; Bera, Sanjib | Kempharm, Inc. | Corrective Assignment to Correct the Doc Date for Guochen Chi and Doc Date for Bindu Bera Previously Recorded on Reel 033580 Frame 0775. Assignor(S) Hereby Confirms the Doc Date Guochen Chi 03/27/2014 and Doc Date for Bindu Bera 03/24/2014. |
| Feb 28, 2020 Reel 51968, frame 714 | Kempharm, Inc. | Deerfield Private Design Fund III, L.P. | Security Interest |
| Jul 9, 2021 Reel 56803, frame 133 | Deerfield Private Design Fund III, L.P. | Kempharm, Inc. | Release of Security Interest |
| Aug 26, 2021 Reel 57322, frame 436 | Guenther, Sven; Chi, Guochen; Bera, Bindu; Mickle, Travis; Bera, Sanjib | Kempharm, Inc. | Corrective Assignment to Correct the Assignee's Address Previously Recorded at Reel: 033648 Frame: 0173. Assignor(S) Hereby Confirms the Assignment. |
| Feb 26, 2024 Reel 66679, frame 668 | Kempharm, Inc. | Zevra Therapeutics, Inc. | Change of Name |
| Apr 8, 2024 Reel 67040, frame 637 | Zevra Therapeutics, Inc. | Alter Domus (US) LLC | Security Interest |
| Mar 13, 2026 Reel 75080, frame 907 | Alter Domus (US) LLC | Zevra Therapeutics, Inc. | Release of Security Interest |
| Mar 25, 2026 Reel 74186, frame 531 | Zevra Therapeutics, Inc. | Commave Therapeutics S.A. | Assignment of Assignor's Interest |
| Mar 26, 2026 Reel 74194, frame 909 | Zevra Therapeutics, Inc. | Commave Therapeutics S.A. | Assignment of Assignor's Interest |
| Sep 11, 2026 Reel 75980, frame 787 | Commave Therapeutics S.A. | Truist Bank, As Administrative Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jul 2032
Term ends Jul 27, 2032. Maintenance fees still fall due before then
Citations
22
later US patents cite this one
That is top 25% of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.